BeOne Medicines (ADR)
Develops and commercializes oncology medicines through an in-house global model.
$366.73
After-hours close−0.03 (−0.01%)
At close$366.76(−1.54%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 32.73%Insiders —
Shares outstanding 106.86M · Float 67.18M · 62.9% free float
Insiders — filings are in the shares behind the receipt.
This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.
Institutions13F, as of Jun 30, 2026
294 holders · 34.97M shares · 47 new positions · 171 increased · 66 reduced · 47 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 8.80M | 8.24% | +2.5K | Aug 14, 2026 |
| Primecap Management Co/CA/ | 5.01M | 4.69% | +32.8K | Aug 14, 2026 |
| Capital International Investors | 4.21M | 3.94% | +51.5K | Aug 12, 2026 |
| FMR LLC | 2.48M | 2.32% | −1.22M | Aug 13, 2026 |
| Capital World Investors | 2.25M | 2.11% | +626.9K | Aug 12, 2026 |
| Citadel Advisors LLC | 1.43M | 1.33% | +393.2K | Aug 14, 2026 |
| Temasek Holdings (Private) Ltd | 845.7K | 0.79% | −16.9K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 758.8K | 0.71% | +219.0K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 8.00% | 13D | Jun 15, 2026 ↗ | |
| Capital International Investors | 5.80% | 13G | May 13, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | Filed |
|---|---|---|---|
| Baker Bros. Advisors LP | director | 730.6K | Feb 28, 2025 |
| Charles Lazelle Sawyers | director | 1.9K | Jun 15, 2026 |
| Shalini Sharp | director | 9 | May 15, 2026 |
16 positions are filed in the unlisted share unit (14.76M shares), which no share count here divides
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 25, 2026 | Xiaobin Wuofficer: President and COO | Sale | 280 | $380.00 | 0 |
| Aug 11, 2026 | Chan Henry Leeofficer: SVP, General Counsel | Sale | 2,666 | $360.00 | 0 |
| Aug 12, 2026 | John Oylerdirector, officer: Chief Executive Officer | Sale · 5 lots | 54,892 | $358.15 | 0 |
| Aug 11, 2026 | John Oylerdirector, officer: Chief Executive Officer | Sale · 9 lots | 70,907 | $361.90 | 54,892 |
| Aug 10, 2026 | John Oylerdirector, officer: Chief Executive Officer | Sale · 10 lots | 115,011 | $357.87 | 125,799 |
| Aug 3, 2026 | Aaron Rosenbergofficer: Chief Financial Officer | Sale | 1,157 | $312.72 | 0 |
| Jul 30, 2026 | Chan Henry Leeofficer: SVP, General Counsel | Sale | 1,044 | $323.69 | 0 |
| Jul 22, 2026 | Chan Henry Leeofficer: SVP, General Counsel | Sale | 1,669 | $325.00 | 0 |
| Jul 21, 2026 | John Oylerdirector, officer: Chief Executive Officer | Sale · 5 lots | 61,397 | $317.67 | 0 |
| Jul 20, 2026 | John Oylerdirector, officer: Chief Executive Officer | Sale · 9 lots | 48,316 | $312.25 | 0 |
CongressHouse and Senate disclosures
Not reported.